Wedbush Predicts Weaker Earnings for Werewolf Therapeutics

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Analysts at Wedbush reduced their FY2025 EPS estimates for shares of Werewolf Therapeutics in a research note issued to investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($1.84) per share for the year, down from their prior forecast of ($0.97). Wedbush has a "Outperform" rating and a $8.00 price objective on the stock. The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Werewolf Therapeutics' FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.63) EPS and FY2029 earnings at ($0.63) EPS.

Several other research firms have also commented on HOWL. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Werewolf Therapeutics in a report on Wednesday, March 12th. JMP Securities dropped their price target on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating on the stock in a research note on Tuesday, January 14th.

Werewolf Therapeutics Stock Performance

HOWL traded down $0.06 during trading hours on Monday, hitting $1.08. 106,640 shares of the stock were exchanged, compared to its average volume of 377,658. The stock has a market cap of $48.19 million, a price-to-earnings ratio of -0.70 and a beta of 0.37. Werewolf Therapeutics has a 12 month low of $1.03 and a 12 month high of $6.89. The stock has a 50-day simple moving average of $1.33 and a 200-day simple moving average of $1.78. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10.

Remove Ads

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. D. E. Shaw & Co. Inc. acquired a new position in shares of Werewolf Therapeutics during the fourth quarter worth approximately $26,000. Regal Investment Advisors LLC increased its holdings in shares of Werewolf Therapeutics by 88.1% during the 4th quarter. Regal Investment Advisors LLC now owns 27,204 shares of the company's stock worth $40,000 after purchasing an additional 12,745 shares during the period. XTX Topco Ltd bought a new stake in shares of Werewolf Therapeutics in the third quarter valued at about $45,000. Levin Capital Strategies L.P. acquired a new stake in Werewolf Therapeutics during the fourth quarter worth about $74,000. Finally, Jane Street Group LLC raised its holdings in Werewolf Therapeutics by 261.2% in the 4th quarter. Jane Street Group LLC now owns 54,713 shares of the company's stock valued at $81,000 after acquiring an additional 39,564 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company's stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.